Streamlining Infectious Disease Eligibility Verification Workflows

The Challenge of Eligibility in Infectious Disease

Infectious disease care often involves high-cost, long-term medications and therapies, such as antivirals for HCV and HIV, advanced antifungals, and Outpatient Parenteral Antibiotic Therapy (OPAT). Manual eligibility verification workflows are prone to errors, leading to stale data, misinterpretation of X12 271 responses, and missed prior authorization requirements that are unique to these specialized treatments. This directly impacts the financial health of the practice and patient access to critical care.

Common Failure Modes in Manual ID Eligibility

• **Stale eligibility data**: Coverage changes mid-period, especially for long-term treatments like HIV regimens or OPAT, leading to denials.
• **Misinterpretation of X12 271 responses**: Complex benefit details for high-cost drugs are often misread, resulting in incorrect patient financial responsibility or missed PA triggers.
• **PA-requirement gaps**: Failure to identify specific prior authorization requirements for high-cost antivirals or antifungals at the eligibility stage.
• **Secondary coverage misses**: Overlooking Medicare-secondary-payer status or coordination of benefits (COB) for complex ID patient populations.
• **Benefit exhaustion**: Eligibility showing active coverage, but specific drug or therapy benefit categories (e.g., infusion services for OPAT) have been exhausted.

Klivira's Automated Infectious Disease Eligibility Verification

Klivira integrates automated eligibility verification as a foundational layer within our prior authorization platform, specifically designed to address the nuances of infectious disease care. Our system automates X12 270/271 eligibility inquiries and FHIR Coverage resource retrieval, parsing complex responses into a normalized model. This ensures accurate, real-time coverage details are available at critical touchpoints, from patient registration to order entry, mitigating financial risk for high-cost ID treatments.

Seamless Integration and Workflow Gating

Our platform writes back eligibility details directly to your EMR, updating Coverage resources or creating structured notes for immediate clinician and administrative visibility. Crucially, when eligibility verification identifies a prior authorization requirement for an infectious disease medication or therapy, Klivira automatically initiates the PA workflow. This closes the operational loop between eligibility and prior authorization, preventing 'PA-not-on-file' denials common with high-cost antivirals, antifungals, and OPAT.

Key Benefits for Infectious Disease Practices

• **Reduced denials for high-cost therapies**: Automated re-verification catches mid-period coverage changes for expensive antivirals, antifungals, and OPAT.
• **Accurate patient financial estimates**: Clearer understanding of copay, coinsurance, and deductible status for ID-specific services and drugs.
• **Proactive PA initiation**: Eligibility-identified PA requirements for specific HIV regimens or infusion services automatically trigger prior authorization workflows.
• **Streamlined EMR integration**: Eligibility data is written back to the EMR, enhancing data integrity and reducing manual entry for infectious disease patient records.
• **Improved revenue cycle efficiency**: Minimizes administrative burden associated with manual eligibility checks, allowing staff to focus on patient care.

Leveraging Industry Standards for ID Eligibility

Klivira utilizes industry-standard protocols to ensure comprehensive eligibility verification for infectious disease patients. We process X12 270/271 transactions for traditional EDI connectivity and leverage FHIR Coverage resources for payers supporting modern APIs, including those mandated by CMS-0057-F Patient Access API requirements. This multi-channel approach ensures maximum payer connectivity and robust data retrieval, crucial for the diverse and often complex insurance landscape of ID patients.